一般社団法人JBCRG学会発表
2025年
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer: results of the randomized JBCRG-22 study
Hiroyuki Yasojima, Norikazu Masuda, Hiroko Bando, Takashi Yamanaka, Hideo Shigematsu, Masato Takahashi, Shigenori E. Nagai, Mitsuya Ito, Tomoyuki Aruga, Mariko Tokiwa, Shigeru Imoto, Rikiya Nakamura, Hiroshi Ishiguro, Hidetaka Kawabata, Shigehira Saji, Hironori Haga, Satoshi Morita, Masakazu Toi
ESMO Breast, 2025 May, Berlin Germany(Poster)
BRCA Genetic Testing Implementation and the Impact of BRCA Pathogenic Variant Status on Clinical Outcomes in HER2-Negative Metastatic and Recurrent Breast Cancer in Japan
Ayaka Sakakibara, Masahiro Ohara, Hiroshi Ishiguro, Naoki Niikura, Yasuaki Sagara, Shigehira Saji, Norikazu Masuda, Akihiko Osaki
ESMO Breast , 2025 May, Berlin Germany(Poster)
Patient-reported fatigue and general pain and the impact on health-related quality of life (HRQoL) in Japanese patients with advanced breast cancer (ABC) treated with palbociclib (PAL) + endocrine therapy (ET): analysis from 6-month observational study (JBCRG-26)
Hiroko Bando, Mari Oba, Aya Ueda, Kaori Terata, Mihoko Doi, Shigenori Nagai, Masaya Hattori, Kenichi Watanabe, Nobuko Tamura, Manabu Futamura, Kei Koizumi, Naoki Niikura, Tempei Miyaji, Yasuaki Muramatsu, Linghua Xu, Asuka Matsui, Norikazu Masuda, Shigehira Saji
ESMO Breast , 2025 May, Berlin Germany(Poster)
Toward personalization of HER2-targeted therapy
Takayuki Ueno, Hiu Ting Chan, Hiroji Iwata, Yutaka Yamamoto
Global Breast Cancer Conference, 2025 Apr, Korea(Poster)